Open AccessAdvantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
Author(s) -
Victoria C. Yan,
Florian L. Muller
Publication year - 2020
Publication title -
acs medicinal chemistry letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 66
ISSN - 1948-5875
DOI - 10.1021/acsmedchemlett.0c00316
Subject(s) - covid-19 , metabolite , nucleoside , medicine , in vivo , virology , nucleoside analogue , pharmacokinetics , pharmacology , chemistry , biology , biochemistry , outbreak , genetics , disease , infectious disease (medical specialty)
While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir evidences premature serum hydrolysis to GS-441524; GS-441524 is the predominant metabolite reaching the lungs. With its synthetic simplicity and in vivo efficacy in the veterinary setting, we contend that GS-441524 is superior to remdesivir for Covid-19 treatment.